Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473406 | 0.91 | ALDH1A1 (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1TNIK | |
| SCHEMBL6032250 | 0.89 | ALDH1A1 (0.35) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL10233489 | 0.88 | GPR52 (0.40) | TNIKAKR1B1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1335730 | 0.87 | AKR1B1 (0.36) | TNIKAKR1B1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL10232272 | 0.86 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL2728768 | 0.85 | GPR52 (0.44) | TNIKAKR1B1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6031924 | 0.85 | PIK3CD (0.39) | TNIKAKR1B1P2RX7PIK3CDPIK3CA | |
| SCHEMBL4478160 | 0.82 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL13672792 | 0.80 | AKR1B1 (0.43) | MEN1KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1336269 | 0.78 | SMN1; SMN2 (0.36) | MEN1KMT2ASMN1; SMN2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | SCHERING CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-7968564-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| EP-1881825-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006121831-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | REV1, POLR1A, POLR2H | MEN1 3932/4885KMT2A 1009/4885SMN1; SMN2 4045/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | MEN1 3937/4885KMT2A 1068/4885SMN1; SMN2 4132/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | MEN1 3937/4885KMT2A 1068/4885SMN1; SMN2 4132/4885 |
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | MEN1 4754/4885KMT2A 1470/4885SMN1; SMN2 4492/4885 |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | MEN1 3937/4885KMT2A 1068/4885SMN1; SMN2 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.